Alternative dry eye disease treatment effective

Article

Sodium hyaluronate (SH) and carboxymethylcellulose (CMC) are safe and effective in treating mild to moderate dry eye disease

Sodium hyaluronate (SH) and carboxymethylcellulose (CMC) are safe and effective in treating mild to moderate dry eye disease, claimed an investigation published in Cornea.

Dr Ji Hwan Lee and his team at The Institute of Vision Research, Department of Ophthalmology, Yonsei University College of Medicine, Seoul, Korea, saw a significant improvement in both SH and CMC groups after treatment.

The prospective, randomized, blind study focused on 67 mild to moderate dry eye patients. There were 32 patients in the SH group and 33 patients in the CMC group. For 8 weeks they were administered preservative-free unit dose formula eyedrops of 0.1% SH or 0.5% CMC 6 times a day. The outcome measures included tear film break-up time, adverse reactions, subjective symptoms and corneal and conjunctival staining with fluorescein. The patients were assessed 4 weeks and 8 weeks after treatment began.

Tear film break-up time, dry eye symptom score and corneal and conjunctival staining significantly improved. There was no significant difference between both groups and no adverse reactions in the follow-up period.

SH and CMC were found to be efficient in the treatment of mild to moderate dry eye disease in the form of a preservative-free artificial tear formulation.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.